Search

Risperidone (generic) — Risperdal (brand) [ABSTRACT FROM AUTHOR]

Risperidone (Generic) – Risperdal (Brand) [ABSTRACT FROM AUTHOR]

Risperidone (generic) – Risperdal (brand) [ABSTRACT FROM AUTHOR]

The main predictor of a child with attention‐deficit/hyperactivity disorder (ADHD) being prescribed psychotropic medications in addition to stimulants is a psychiatric consultation, according to a new study from Canada. Researchers looked at children in Ontario to determine the predictors of medication prescription for ADHD in youth, as well as the prevalence and characteristics of youth with ADHD. [ABSTRACT FROM AUTHOR]

Risperidone (generic) Risperdal (brand) [ABSTRACT FROM AUTHOR]

Atypical antipsychotic medications in children with autism spectrum disorder (ASD) are indicated for related irritability and agitation. These medications are associated with weight gain and metabolic complications, so researchers wanted to evaluate the efficacy of metformin. [ABSTRACT FROM AUTHOR]

The article presents study investigating the benefits of adding a drug risperidone to initial treatment with a stimulant in preadolescent nonresponders with attention-deficit/ hyperactivity disorder (ADHD), disruptive behavior disorders, and severe aggression. It is mentioned that combination treatment offers fewer side effects than with either drug used alone.

Researchers on the Treatment of Early Age Mania (TEAM) study assessed the effectiveness of three study medications - lithium, risperidone, and divalproex - in children with bipolar I disorder to find out whether an add-on or a switch of medications for an 8-week trial would be effective for partial responders and nonresponders to one of the medications. [ABSTRACT FROM AUTHOR]

While risperidone has been shown to be effective for short‐term (8‐week and 6‐month) management of severe irritability and aggression in children and adolescents with autism, less is known about long‐term effects. Researchers looked at tolerability, safety, and therapeutic benefits of long‐term use of the medication and found that the risks — weight gain, enuresis, and increased appetite — were balanced by the benefits. [ABSTRACT FROM AUTHOR]

Risperidone (generic) Risperdal (brand) [ABSTRACT FROM AUTHOR]

Stimulant Treatment for ADHD can Retard Rate of Weight Growth, Especially at Higher Doses Effects of Midazolam on Memory in Pediatric Surgery Settings Research Review Raises Cause for Concern on Height Effects Risperidone in Children, Adolescents and Adults with MR Modafinil for ADHD in Children and Adolescents Effect of Low-Dose Methylphenidate on Comorbid ADHD/SUDs Limited Spike in Antipsychotic use Among Children Brain Development Differs in Highly Intelligent Children Psychosocial Functioning in Adolescents with BD Early Bicarbonate Loading and Datroline for NMS Approval: Naltrexone Extended-Release Injectable (Vivitrol) Warning: Promethazine HCl [ABSTRACT FROM AUTHOR]

Reports on the use of risperidone to treat autism and closely related disorders such as pervasive developmental disorder. Use of Irritability Subscale of the Aberrant Behavior Checklist and Clinical Global Impressions; Reduction in the irritability score; Common side effect.

There are no known pharmacotherapies for autism spectrum disorder (ASD); however, clinicians commonly prescribe psychotropic medication for behaviors and symptoms associated with ASD. Researchers conducted a review of studies looking at which medications work for what behaviors and symptoms. [ABSTRACT FROM AUTHOR]

The article discusses a study which examines the effectiveness of a therapy augmented with risperidone in children with attention-deficit hyperactivity disorder (ADHD) or oppositional defiant disorder (ODD) based on parent and teacher ratings. Findings reveal that parent and teacher ratings have different assessments about the capacity of the therapy to reduce ADHD and ODD symptoms. The discrepancy in the ratings is caused by the challenges associated to the identification of the diseases.

The article discusses information about risperidone, which is in a class of medications called atypical antipsychotics. It has indications for the treatment of schizophrenia in adults and in adolescents aged 13 to 17. There is possibility for an increased risk of rapid weight gain in children and adolescents. Doses are started low and increased slowly based on clinical response and side effects.

The article reports on a study that led to a conclusion among researchers to disregard antipsychotic medication as first-line therapy for young people who are at ultra-high risk of psychosis. Researchers have noted same levels of improvement among patients treated in three groups wherein 25 out of 115 have transitioned to psychosis. No significant differences have been detected within the treatment groups in terms on the rate of transition but in the placebo and supportive therapy group.

The article focuses on a follow-up study for a trial which compared the use of risperidone to medications in combination with parent training for behavioral management in children with autism spectrum disorders and severe irritability. The study shows that the advantage of combination treatment over medication alone dissipated by more than half one year after completion of the original study. The researchers found no significant differences in medication use between the two treatment groups.

The article discusses the findings of a study that examines the moderators and predictors of treatment outcome in bipolar mania. The study included 279 youths with bipolar mania. It reveals that risperidone treatment is better than lithium and divalproex, but the result was influenced by treatment site. It also suggests that risperidone is more effective than lithium in patients with attention-deficit hyperactivity disorder (ADHD).

The article reports on an Australian study which examines how various interventions during the prodromal phase of illness worked to delay or even prevent the onset of psychosis. Researcher Alison R. Yung and colleagues studied whether risperidone with cognitive behavioral therapy (CBT), placebo with CBT, and placebo with supportive therapy prevented the onset of psychosis in youth. It states that researchers found little difference in outcome from the use of risperidone compared to placebo.

The article reports on the study published in the "Journal of the American Academy of Child and Adolescent Psychiatry" which examines the effectiveness of combined treatment of risperidone and 11 parent training (PT) sessions on improving pervasive developmental disorders (PDD) in the U.S. Author Michael G. Aman of Ohio State University states that the affordability of the PTs makes its role in the treatment of PDDs noteworthy. Children between 4 to 13 years old with PDD were the study subjects.

The article reports on the research made by Magali Haas on the efficacy of risperidone to treat acute manic symptoms on youths with bipolar I disorders. Researchers treated patients on a daily dose of 0.5 to 2.5 milligrams or three to six mg of drug for three weeks. Results show that those who received risperidone experienced improved manic symptoms compared to those with placebo.

The article presents a research review that found no evidence in supporting the use of the antiseptic medication risperidone for the treatment of attention-deficit/hyperactivity disorder (ADHD).It mentions the of two studies where no indluded because they did not separate the result for a subgroup with the co-occurring ADHD and intellectual disabilities. It emphasizes that resperindone should not be the first-line treatment for ADHD.

The article reports on the development of a major National Institutes of Health (NIH) study on the treatment of early-onset schizophrenia spectrum disorders (TEOSS) in the U.S. It is said that the study is a multicenter clinical trial designed to compare the effects of risperidone, olanzapine, and molindone on youth aging from eight to 19, in which data collection will be completed within 2007. Further discussions of the development are presented.

The article presents a meta-analysis of 14 short-term medication trials for the treatment of disruptive behavior disorders, mainly conduct disorder. The researchers revealed that various medications, including methylphenidate, lithium and risperidone, showed positive results on measures of treatment response and symptom severity. However, researchers warned that the effectiveness of medications of lithium and risperidone must be weighed against the risk of side effects for young patients.

The article highlights the results of a study which suggests that children and adolescents with disruptive behavior disorders who respond to an initial 12 weeks of treatment with risperidone continue to benefit under six months of treatment with the antipsychotic medication. The research team was led by Dr. Magali Reyes. The study found that time to symptom recurrence was longer for young patients on risperidone maintenance treatment when compared with patients switched from risperidone to placebo.

Reports on a study of the effects of risperidone or Risperdal on the core symptoms of autism. Effectiveness of the drug in reducing repetitive and stereotyped patterns of behavior; Comparison with the effect of placebo on language impairment and the qualitative impairment in social interaction. INSETS: Method and Design;About Research Units on Pediatric Psychopharmacology (RUPPs);FDA issues a "Not Approvable" letter for Risperdal treatment....

Reports that risperidone reduced the severity of affective symptoms in children with disruptive behavior disorders and subaverage IQ, according to an analysis of data from a multicenter study. Conclusion of researchers that risperidone therapy for six weeks reduced the severity of the affective syndromes as well as behavioral symptoms in the described children.

Reports on the completion of two different medications a dopamine antagonist risperidone and a dopamine agonist pergolide in clinical trials for alternative research in the treatment of Tourette Syndrome. Incidence of social phobia in risperidone study; Decrease of tic severity by using pergolide; Emphasis on the treatment of tics when causing a problem for a child.

Highlights on the findings of a study on the efficacy of antipsychotics in patients with childhood-onset schizophrenia. Weight gain in patients; Side effects observed with the antipsychotic agents; Levels of prolactin; Occurrence of hyperlipidemia; Efficacy of risperidone against conduct disorder in children. INSET: Clinical Consult.

The article provides information on risperidone, a class of medications called atypical antipsychotics. Topics mentioned include the major potential risks and side effects of risperidone therapy, pediatric use for irritability associated with autistic disorder, and storage of risperidone tablets and oral solution.

Little is known about the impact of antipsychotic medication on movement disorders in young patients a few years after disease onset, but a recent study shows a surprisingly high rate of such disorders in young people only four years after the onset of the disease. Researchers used the Genetic Risk and Outcome of Psychosis (GROUP) study to assess the prevalence, incidence, persistence, and clinical correlates of drug-related movement disorders on young patients. [ABSTRACT FROM AUTHOR]

The article offers information about the risperidone, its use, and risk and effects associated with it. It mentions that risperidone is in a class of medications that call atypical antipsychotics, and states that it is approved by the U.S. Food and Drug Administration (FDA)approved indications for the treatment of schizophrenia in adults and in adolescents. It also mentions several potential risks and side effects of risperidone therapy such as it increase mortality in elderly patients.

Whole exome sequencing (WES) is done to find a genetic cause of signs and symptoms; it looks at more genes than most genetic tests, and may find a cause that previous testing did not. [ABSTRACT FROM AUTHOR]

Iron deficiency results in cognitive deficits in rodents, which can be reversed with stimulants. In humans, iron deficiency causes behavioral and neuropsychological impairments, both with or without anemia. For children with attention-deficit hyperactivity disorder (ADHD), low ferritin - a marker of body iron stores - has been associated with more severe symptoms and a poorer response to psychostimulants. [ABSTRACT FROM AUTHOR]

The article presents updates related to the generic atypical antipsychotic drug risperidone. Information provided include the use of risperidone, major potential risks and side effects of risperidone therapy, and potential interactions of risperidone with other drugs or foods. Tips on how to take and store risperidone tablets and oral solution are also offered.

Children with autism spectrum disorder (ASD) have impairments in social communications and restricted repetitive behaviors as core symptoms. They also have a high incidence of irritability, aggression, and hyperactivity. While there is no medication approved for core symptoms of ASD, risperidone and aripiprazole have been approved for irritability and aggression associated with ASD. [ABSTRACT FROM AUTHOR]

The article offers information related to atypical antipsychotics Risperidone. Topics discussed include the function of the medicine as treatment for schizophrenia in adolescents and adults, risks and side effects forutilization of the drug including neuroleptic malignant syndrome (NMS), tardive dyskinesia (TD), and hyperglycemia, and doses for intake of the drug.

The article focuses on the study on the association of long-term risperidone to sexual effects in young males with autism spectrum disorders or disruptive behavior disorders. The study was participated by a total of 98 young males who were recruited from an outpatient adolescent clinic in the Netherlands. The result of the study shows that problems reported include diminished ability to have an orgasm and diminished ejaculation.

The article reports on a study that found high rates of hyperprolactinemia among risperidone-treated youth. Results indicated a possibility of gynecomastia and sexual dysfunction in relation to risperidone treatment. Researchers have further concluded that hyperprolactinemia is a common side effect among individuals undergoing long term treatment with risperidone.

The article offers information about the atypical antipsychotics risperidone. It notes that the drug has Food and Drug Administration (FDA)-approved indications for the treatment of schizophrenia and short-term treatment of acute mania or mixed episodes associated with bipolar disorder. Also offered are the potential risks and side effects of risperidone therapy as well as there interactions with drugs or foods.

The article reports on an exploratory pilot study which found no significant benefits of risperidone in treating anorexia nervosa (AN) in teenagers. The aims of the study were to examine whether AN patients randomized to risperidone would show decreases in their drive for thinness, body dissatisfaction and body distortion image. Result shows that there is no sufficient evidence to support recommending atypical neuroleptic drugs for the treatment of AN.

The article focuses on the comprehensive review of prospective head-to-head and placebo-controlled studies on the safety and efficacy of the second-generation antipsychotics (SGAs) in children and adolescents with psychotic and bipolar spectrum disorders. The study assessed the efficacy and safety data of 34 studies on SGAs. The study found that the efficacy between different SGAs and between SGAs and first- generation antipsychotics (FGAs) is similar to pediatric patients except for clozapine.

The article provides updates on clinical studies in the U.S. A study by researcher Ayten Erdogan and colleagues investigated the changes in liver function tests (LFTs) associated with more than six months of risperidone treatment in children and adolescents. A study by researcher Gagan Joshi and colleagues examined the safety, tolerability and efficacy of quetiapine monotherapy for the treatment of preschool and school-age children with bipolar disorder (BPD).

The article offers guidelines on aspects of Risperidone which is in a class of medications called atypical antipsychotics. As stated, the said drug has indications approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and in adolescents who are aged 13 to 17. Some of the major potential risks and side effects of risperidone therapy are offered. Information about the dosage of the said drug is also provided.

The article reports on a study conducted by Robert L. Findling comparing the acute effectiveness and safety of risperidone, olanzapine, and molindone in adolescents with early-onset schizophrenia spectrum (EOSS) disorders in the U.S. A total of 116 youths participated in the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. Results of the study showed no clinically significant difference in symptom improvement with risperidone, olanzapine, and molindone over 52 weeks of treatment.

The article presents a study which analyzed the medical records of 83 boys treated with risperidone. It states that there were no significant differences at baseline between subjects with or with out hyperprolactinemia. Around half (49%) of those boys treated with risperidone had hyperprolactinemia, however the duration of treatment did not have an effect on bone mineral density. It also found that selective serotonin reuptake inhibitors (SSRIs) were associated with lower trabecular BMD.